Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20355)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR50 | GRmax | GR_AOC | GEC50 | GRinf | GR Hill Coefficient | GR r2 | pval_GR |
|---|---|---|---|---|---|---|---|---|---|
| HCC1500 | BMS-265246 | -inf | 0.2444 | 0.9257 | 0.0000 | 0.1272 | 0.0100 | 0.0000 | 1.0 |
| HCC1806 | THZ1 | -inf | -0.5805 | ||||||
| HCC1500 | Ulixertinib | -inf | 0.3396 | ||||||
| HCC1500 | Alvocidib | -inf | -0.9990 | ||||||
| HCC1500 | SHP099 | -inf | -0.1868 | ||||||
| MDA-MB-134-VI | AZD2014 | -inf | -0.7122 | ||||||
| MDA-MB-134-VI | AZD5363 | -inf | 0.3909 | ||||||
| MDA-MB-134-VI | AZD6738 | -inf | 0.1117 | ||||||
| HCC1954 | BMS-265246 | -inf | -0.1012 | ||||||
| MDA-MB-134-VI | BMS-265246 | -inf | 0.0268 | ||||||
| MCF 10A | Alvocidib | -inf | -0.7589 | ||||||
| MDA-MB-134-VI | Ulixertinib | -inf | -0.2948 | ||||||
| Hs 578T | BMS-265246 | -inf | |||||||
| MDA-MB-134-VI | Alvocidib | -inf | -0.4621 | ||||||
| HCC1428 | Senexin B | -inf | -0.2008 | 0.6803 | 0.0000 | 0.2756 | 0.0100 | 0.0000 | 0.123657155 |
| MDA-MB-157 | Ulixertinib | -inf | 0.3233 | ||||||
| MDA-MB-134-VI | Rucaparib | #NAME? | 0.6274 | ||||||
| HCC1500 | Rucaparib | #NAME? | 1.0742 | 0.0000 | 0.1000 | 0.0100 | |||
| HCC1428 | Ribociclib | #NAME? | -0.3849 | 0.7838 | 0.0000 | 0.2963 | 0.0100 | 0.0000 | 0.210923138 |